JP6733072B2 - ジヒドロクロメン誘導体 - Google Patents

ジヒドロクロメン誘導体 Download PDF

Info

Publication number
JP6733072B2
JP6733072B2 JP2020507833A JP2020507833A JP6733072B2 JP 6733072 B2 JP6733072 B2 JP 6733072B2 JP 2020507833 A JP2020507833 A JP 2020507833A JP 2020507833 A JP2020507833 A JP 2020507833A JP 6733072 B2 JP6733072 B2 JP 6733072B2
Authority
JP
Japan
Prior art keywords
methyl
piperidine
pyrano
spiro
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020507833A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019181939A1 (ja
Inventor
坂 仁志
仁志 坂
正児 上岡
正児 上岡
裕介 澤山
裕介 澤山
美紀 橋詰
美紀 橋詰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JPWO2019181939A1 publication Critical patent/JPWO2019181939A1/ja
Application granted granted Critical
Publication of JP6733072B2 publication Critical patent/JP6733072B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
JP2020507833A 2018-03-20 2019-03-19 ジヒドロクロメン誘導体 Active JP6733072B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018052971 2018-03-20
JP2018052971 2018-03-20
PCT/JP2019/011439 WO2019181939A1 (ja) 2018-03-20 2019-03-19 ジヒドロクロメン誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020117566A Division JP7247144B2 (ja) 2018-03-20 2020-07-08 ジヒドロクロメン誘導体

Publications (2)

Publication Number Publication Date
JPWO2019181939A1 JPWO2019181939A1 (ja) 2020-06-18
JP6733072B2 true JP6733072B2 (ja) 2020-07-29

Family

ID=67986459

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020507833A Active JP6733072B2 (ja) 2018-03-20 2019-03-19 ジヒドロクロメン誘導体
JP2020117566A Active JP7247144B2 (ja) 2018-03-20 2020-07-08 ジヒドロクロメン誘導体
JP2023040667A Active JP7508620B2 (ja) 2018-03-20 2023-03-15 ジヒドロクロメン誘導体
JP2024098472A Pending JP2024123117A (ja) 2018-03-20 2024-06-19 ジヒドロクロメン誘導体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020117566A Active JP7247144B2 (ja) 2018-03-20 2020-07-08 ジヒドロクロメン誘導体
JP2023040667A Active JP7508620B2 (ja) 2018-03-20 2023-03-15 ジヒドロクロメン誘導体
JP2024098472A Pending JP2024123117A (ja) 2018-03-20 2024-06-19 ジヒドロクロメン誘導体

Country Status (21)

Country Link
US (3) US10807993B2 (https=)
EP (1) EP3770162B1 (https=)
JP (4) JP6733072B2 (https=)
KR (1) KR102799186B1 (https=)
CN (1) CN111886237B (https=)
AU (1) AU2019239481B2 (https=)
CA (1) CA3092255A1 (https=)
CY (1) CY1126034T1 (https=)
DK (1) DK3770162T3 (https=)
EA (1) EA202092206A1 (https=)
ES (1) ES2941771T3 (https=)
FI (1) FI3770162T3 (https=)
HU (1) HUE062256T2 (https=)
MX (1) MX2020009763A (https=)
MY (1) MY202583A (https=)
PH (1) PH12020551497A1 (https=)
PL (1) PL3770162T3 (https=)
PT (1) PT3770162T (https=)
SG (1) SG11202007979UA (https=)
TW (1) TWI899051B (https=)
WO (1) WO2019181939A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020180140A (ja) * 2018-03-20 2020-11-05 大日本住友製薬株式会社 ジヒドロクロメン誘導体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2025100519A1 (ja) * 2023-11-09 2025-05-15 住友ファーマ株式会社 ジヒドロクロメン誘導体を含むがんの治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045707A1 (en) 1999-12-21 2001-06-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20090111805A1 (en) 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US20080255149A1 (en) * 2005-09-27 2008-10-16 Novartis Ag Carboxyamine Compounds and Methods of Use Thereof
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
RU2018101897A (ru) * 2015-06-22 2019-07-24 Сумитомо Дайниппон Фарма Ко., Лтд. Бициклическое гетероциклическое амидное производное
CA2990583A1 (en) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
JP6896701B2 (ja) * 2016-02-26 2021-06-30 大日本住友製薬株式会社 イミダゾリルアミド誘導体
TW201821105A (zh) * 2016-10-20 2018-06-16 美商弗瑪治療公司 使用hdac11抑制劑之方法
PL3770162T3 (pl) 2018-03-20 2023-06-05 Sumitomo Pharma Co., Ltd. Pochodne dihydrochromenu
JP2020019752A (ja) 2018-08-03 2020-02-06 大日本住友製薬株式会社 クロマン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020180140A (ja) * 2018-03-20 2020-11-05 大日本住友製薬株式会社 ジヒドロクロメン誘導体

Also Published As

Publication number Publication date
KR102799186B1 (ko) 2025-04-23
CN111886237A (zh) 2020-11-03
US20230219970A1 (en) 2023-07-13
US20200216461A1 (en) 2020-07-09
MX2020009763A (es) 2020-10-08
JP2024123117A (ja) 2024-09-10
FI3770162T3 (fi) 2023-06-02
AU2019239481A1 (en) 2020-09-10
KR20200135401A (ko) 2020-12-02
CA3092255A1 (en) 2019-09-26
US20210002290A1 (en) 2021-01-07
EP3770162B1 (en) 2023-03-15
BR112020017481A8 (pt) 2022-12-06
CY1126034T1 (el) 2023-11-15
JPWO2019181939A1 (ja) 2020-06-18
SG11202007979UA (en) 2020-09-29
US10807993B2 (en) 2020-10-20
DK3770162T3 (da) 2023-04-24
EP3770162A4 (en) 2021-12-01
US11639357B2 (en) 2023-05-02
EP3770162A1 (en) 2021-01-27
PL3770162T3 (pl) 2023-06-05
HUE062256T2 (hu) 2023-10-28
MY202583A (en) 2024-05-09
US12398149B2 (en) 2025-08-26
CN111886237B (zh) 2025-02-07
JP7508620B2 (ja) 2024-07-01
ES2941771T3 (es) 2023-05-25
EA202092206A1 (ru) 2020-12-15
JP2023075288A (ja) 2023-05-30
NZ767234A (en) 2025-06-27
JP2020180140A (ja) 2020-11-05
AU2019239481B2 (en) 2022-11-24
BR112020017481A2 (pt) 2020-12-22
PT3770162T (pt) 2023-03-23
JP7247144B2 (ja) 2023-03-28
TWI899051B (zh) 2025-10-01
PH12020551497A1 (en) 2021-09-01
WO2019181939A1 (ja) 2019-09-26
TW201941774A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
JP7508620B2 (ja) ジヒドロクロメン誘導体
AU2014259477B2 (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors for the treatment of cancer
US12364702B2 (en) Highly active sting protein agonist compound
JP2020105191A (ja) 光学活性なアザビシクロ環誘導体
US12492197B2 (en) 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
WO2021060453A1 (ja) 架橋型光学活性2級アミン誘導体
JPWO2019189732A1 (ja) 光学活性な架橋型環状2級アミン誘導体
US20230399327A1 (en) High activity hpk1 kinase inhibitor
JP7287929B2 (ja) ジヒドロクロメン誘導体を含有する医薬
JP2020019752A (ja) クロマン誘導体
WO2021172359A1 (ja) Cdk9阻害剤プロドラッグ及びそれを内封するリポソーム
AU2020342189B2 (en) 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
US11780843B2 (en) Compounds active towards nuclear receptors
EP4495111A1 (en) Novel compound and use thereof for inhibiting checkpoint kinase 2
HK40043696B (en) Dihydrochromene derivatives
HK40043696A (en) Dihydrochromene derivatives
BR112020017481B1 (pt) Derivados de di-hidrocromeno, seu uso e composição farmacêutica
HK40048031A (en) Highly active sting protein agonist compound
EA041753B1 (ru) Производные дигидрохромена

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200311

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200311

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200708

R150 Certificate of patent or registration of utility model

Ref document number: 6733072

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250